- Home
- RVT vs ADPT Comparison
RVT vs ADPT Comparison
Compare RVT & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVT
- ADPT
- Stock Information
- Founded
- RVT 1986
- ADPT 2009
- Country
- RVT United States
- ADPT United States
- Employees
- RVT N/A
- ADPT N/A
- Industry
- RVT Trusts Except Educational Religious and Charitable
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RVT Finance
- ADPT Health Care
- Exchange
- RVT Nasdaq
- ADPT Nasdaq
- Market Cap
- RVT 1.8B
- ADPT 1.8B
- IPO Year
- RVT N/A
- ADPT 2019
- Fundamental
- Price
- RVT $15.92
- ADPT $13.00
- Analyst Decision
- RVT
- ADPT Strong Buy
- Analyst Count
- RVT 0
- ADPT 8
- Target Price
- RVT N/A
- ADPT $12.38
- AVG Volume (30 Days)
- RVT 243.4K
- ADPT 2.2M
- Earning Date
- RVT 01-01-0001
- ADPT 08-05-2025
- Dividend Yield
- RVT 7.32%
- ADPT N/A
- EPS Growth
- RVT N/A
- ADPT N/A
- EPS
- RVT 2.95
- ADPT N/A
- Revenue
- RVT N/A
- ADPT $205,216,000.00
- Revenue This Year
- RVT N/A
- ADPT $24.39
- Revenue Next Year
- RVT N/A
- ADPT $20.44
- P/E Ratio
- RVT $4.98
- ADPT N/A
- Revenue Growth
- RVT N/A
- ADPT 21.60
- 52 Week Low
- RVT $11.85
- ADPT $3.98
- 52 Week High
- RVT $14.93
- ADPT $13.40
- Technical
- Relative Strength Index (RSI)
- RVT 64.08
- ADPT 64.48
- Support Level
- RVT $15.34
- ADPT $12.10
- Resistance Level
- RVT $15.67
- ADPT $13.37
- Average True Range (ATR)
- RVT 0.22
- ADPT 0.87
- MACD
- RVT 0.03
- ADPT 0.06
- Stochastic Oscillator
- RVT 86.96
- ADPT 85.74
About RVT Royce Value Trust Inc.
Royce Value Trust Inc is a diversified closed-end investment company. It invests in diversified sectors including consumer discretionary, consumer staples, healthcare, financial, IT, telecommunications, and materials. The company's portfolio includes common stocks, preferred stocks, corporate bonds, and repurchase agreements. The company invests in Industrials, Financials, Information Technology, Materials, Health Care, Communication Services, Real Estate and others.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).